View in EDS PDF Full Text

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Saved in:
Bibliographic Details
Title: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Authors: Schnitzer TJ (AUTHOR), Burmester GR (AUTHOR), Mysler E (AUTHOR), Hochberg MC (AUTHOR), Doherty M (AUTHOR), Ehrsam E (AUTHOR), Gitton X (AUTHOR), Krammer G (AUTHOR), Mellein B (AUTHOR), Matchaba P (AUTHOR), Gimona A (AUTHOR), Hawkey CJ (AUTHOR), TARGET (Therapeutic Arthritis Research and Gastrointestinal Event Trial) Study Group (CORPORATE AUTHOR), Schnitzer, Thomas J (AUTHOR), Burmester, Gerd R (AUTHOR), Mysler, Eduardo (AUTHOR), Hochberg, Marc C (AUTHOR), Doherty, Michael (AUTHOR), Ehrsam, Elena (AUTHOR), Gitton, Xavier (AUTHOR)
Source: Lancet. 8/21/2004, Vol. 364 Issue 9435, p665-674. 10p.
Abstract: Background: Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce ulcer complications compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is limited, and the possibility that these inhibitors increase cardiovascular events has been raised. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen.Methods: 18325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) for 52 weeks, in two substudies of identical design (lumiracoxib vs ibuprofen or naproxen). Randomisation was stratified for low-dose aspirin use and age. The primary endpoint was the difference in time-to-event distribution of upper gastrointestinal ulcer complications (bleeding, perforation, or obstruction); analysis was by modified intention to treat. The principle measure of adverse cardiovascular events was the Antiplatelet Trialists' Collaboration endpoint (myocardial infarction, stroke, or cardiovascular death); this analysis was intention to treat.Findings: 81 (0.44%) patients did not start treatment and 7120 (39%) did not complete the study. In patients not taking aspirin, the cumulative 1-year incidence of ulcer complications was 1.09% (95% CI 0.82-1.36) with non-steroidal anti-inflammatory drugs (64 events) versus 0.25% (95% CI 0.12-0.39) with lumiracoxib (14 events; hazard ratio 0.21 [95% CI 0.12-0.37], p<0.0001). Reductions in ulcer complications were also significant in the overall population (0.34 [0.22-0.52], p<0.0001) but not in those taking aspirin (0.79 [0.40-1.55], p=0.4876). In the overall population, 0.55% (50/9127) of those on non-steroidal anti-inflammatory drugs and 0.65% (59/9117) of those on lumiracoxib reached the cardiovascular endpoint (1.14 [0.78-1.66], p=0.5074).Interpretation: Lumiracoxib showed a three to four-fold reduction in ulcer complications compared with non-steroidal anti-inflammatory drugs without an increase in the rate of serious cardiovascular events, suggesting that lumiracoxib is an appropriate treatment for patients with osteoarthritis. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 106673136
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Schnitzer+TJ%22&quot;&gt;Schnitzer TJ&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Burmester+GR%22&quot;&gt;Burmester GR&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mysler+E%22&quot;&gt;Mysler E&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hochberg+MC%22&quot;&gt;Hochberg MC&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Doherty+M%22&quot;&gt;Doherty M&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ehrsam+E%22&quot;&gt;Ehrsam E&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gitton+X%22&quot;&gt;Gitton X&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Krammer+G%22&quot;&gt;Krammer G&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mellein+B%22&quot;&gt;Mellein B&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Matchaba+P%22&quot;&gt;Matchaba P&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gimona+A%22&quot;&gt;Gimona A&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hawkey+CJ%22&quot;&gt;Hawkey CJ&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22TARGET+%28Therapeutic+Arthritis+Research+and+Gastrointestinal+Event+Trial%29+Study+Group%22&quot;&gt;TARGET (Therapeutic Arthritis Research and Gastrointestinal Event Trial) Study Group&lt;/searchLink&gt; (CORPORATE AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Schnitzer%2C+Thomas+J%22&quot;&gt;Schnitzer, Thomas J&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Burmester%2C+Gerd+R%22&quot;&gt;Burmester, Gerd R&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mysler%2C+Eduardo%22&quot;&gt;Mysler, Eduardo&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hochberg%2C+Marc+C%22&quot;&gt;Hochberg, Marc C&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Doherty%2C+Michael%22&quot;&gt;Doherty, Michael&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ehrsam%2C+Elena%22&quot;&gt;Ehrsam, Elena&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gitton%2C+Xavier%22&quot;&gt;Gitton, Xavier&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. 8/21/2004, Vol. 364 Issue 9435, p665-674. 10p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: &lt;bold&gt;Background: &lt;/bold&gt;Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce ulcer complications compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is limited, and the possibility that these inhibitors increase cardiovascular events has been raised. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen.&lt;bold&gt;Methods: &lt;/bold&gt;18325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) for 52 weeks, in two substudies of identical design (lumiracoxib vs ibuprofen or naproxen). Randomisation was stratified for low-dose aspirin use and age. The primary endpoint was the difference in time-to-event distribution of upper gastrointestinal ulcer complications (bleeding, perforation, or obstruction); analysis was by modified intention to treat. The principle measure of adverse cardiovascular events was the Antiplatelet Trialists&#39; Collaboration endpoint (myocardial infarction, stroke, or cardiovascular death); this analysis was intention to treat.&lt;bold&gt;Findings: &lt;/bold&gt;81 (0.44%) patients did not start treatment and 7120 (39%) did not complete the study. In patients not taking aspirin, the cumulative 1-year incidence of ulcer complications was 1.09% (95% CI 0.82-1.36) with non-steroidal anti-inflammatory drugs (64 events) versus 0.25% (95% CI 0.12-0.39) with lumiracoxib (14 events; hazard ratio 0.21 [95% CI 0.12-0.37], p&lt;0.0001). Reductions in ulcer complications were also significant in the overall population (0.34 [0.22-0.52], p&lt;0.0001) but not in those taking aspirin (0.79 [0.40-1.55], p=0.4876). In the overall population, 0.55% (50/9127) of those on non-steroidal anti-inflammatory drugs and 0.65% (59/9117) of those on lumiracoxib reached the cardiovascular endpoint (1.14 [0.78-1.66], p=0.5074).&lt;bold&gt;Interpretation: &lt;/bold&gt;Lumiracoxib showed a three to four-fold reduction in ulcer complications compared with non-steroidal anti-inflammatory drugs without an increase in the rate of serious cardiovascular events, suggesting that lumiracoxib is an appropriate treatment for patients with osteoarthritis. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=106673136
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(04)16893-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 665
    Titles:
      – TitleFull: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Schnitzer TJ
      – PersonEntity:
          Name:
            NameFull: Burmester GR
      – PersonEntity:
          Name:
            NameFull: Mysler E
      – PersonEntity:
          Name:
            NameFull: Hochberg MC
      – PersonEntity:
          Name:
            NameFull: Doherty M
      – PersonEntity:
          Name:
            NameFull: Ehrsam E
      – PersonEntity:
          Name:
            NameFull: Gitton X
      – PersonEntity:
          Name:
            NameFull: Krammer G
      – PersonEntity:
          Name:
            NameFull: Mellein B
      – PersonEntity:
          Name:
            NameFull: Matchaba P
      – PersonEntity:
          Name:
            NameFull: Gimona A
      – PersonEntity:
          Name:
            NameFull: Hawkey CJ
      – PersonEntity:
          Name:
            NameFull: TARGET (Therapeutic Arthritis Research and Gastrointestinal Event Trial) Study Group
      – PersonEntity:
          Name:
            NameFull: Schnitzer, Thomas J
      – PersonEntity:
          Name:
            NameFull: Burmester, Gerd R
      – PersonEntity:
          Name:
            NameFull: Mysler, Eduardo
      – PersonEntity:
          Name:
            NameFull: Hochberg, Marc C
      – PersonEntity:
          Name:
            NameFull: Doherty, Michael
      – PersonEntity:
          Name:
            NameFull: Ehrsam, Elena
      – PersonEntity:
          Name:
            NameFull: Gitton, Xavier
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 08
              Text: 8/21/2004
              Type: published
              Y: 2004
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 364
            – Type: issue
              Value: 9435
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1